COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Eli Lilly And Co.
LY-CoV555, an antibody therapeutic for treatment and prevention of COVID-19
Phase 3 trial OF LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 (BLAZE-2)
Privately-held AbCellera Biologics Inc., National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center
Cerecor Inc.
CERC-002 is under phase 2 proof-of-concept trial in patients with COVID-19 cytokine storm-induced Acute Respiratory Distress Syndrome
Top-line data expected in the fourth quarter of 2020
Moderna, Inc
mRNA-1273 Vaccine
Phase 2 study underway, Phase 3 study (COVE) began on July 27
Phase 3 COVE data to be available by Thanksgiving (November)
Immunic, Inc
IMU-838 for COVID-19.
Phase 2 study in combination with Tamiflu in adult patients with moderate-to-severe COVID-19 (IONIC)
Top-line data expected later in 2020
University Hospitals Coventry and Warwickshire NHS Trust
Anti-Addiction patch for extracorporeal treatment
Anti-Addiction patch to remove disease-causing antigens and to prevent the “cytokine storm” associated with the disease in severely ill patients is under research stage
Halberd Corporation and Gold River Productions Inc.
Merck & Co Inc.
V590, a SARS-CoV-2 vaccine candidate
Preclinical development
Clinical studies of V590 to start this year
The International AIDS Vaccine Initiative (IAVI)
Oragenics Inc.
TerraCoV2 Vaccine
Begin human clinical trials of TerraCoV2 vaccine by early 2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in... Google parent Alphabet Inc. has issued $5.75 billion in sustainability bonds, becoming the largest green or sustainability bonds issued by a company until now. This is part of a $10 billion debt offering. Alphabet said the proceeds will be used to fund projects that are environmentally or socially responsible.